[1]张盈莹,卓永,欧佩,等.尿NGAL及KIM-1水平对藏区糖尿病 肾脏病的临床诊断价值研究[J].国际内分泌代谢杂志,2020,40(05):294-299.[doi:10.3760/cma.j.cn121383-20200502-05027]
　Zhang Yingying,Zhuo Yong,Ou Pei,et al.The clinical diagnostic value of urine NGAL and KIM-1 in diabetic kidney disease in Tibet area of China[J].International Journal of Endocrinology and Metabolism,2020,40(05):294-299.[doi:10.3760/cma.j.cn121383-20200502-05027]
点击复制

尿NGAL及KIM-1水平对藏区糖尿病 肾脏病的临床诊断价值研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
294-299
栏目:
论著
出版日期:
2020-09-20

文章信息/Info

Title:
The clinical diagnostic value of urine NGAL and KIM-1 in diabetic kidney disease in Tibet area of China
作者:
张盈莹1; 卓永2; 欧佩2; 李晨光1; 赵耕1; 2
1天津医科大学朱宪彝纪念医院检验科,国家卫生健康委员会激素与发育重点实验室(天津医科大学),天津市代谢性疾病重点实验室,天津医科大学朱宪彝纪念医院&天津市内分泌研究所 300134; 2西藏自治区昌都市藏医院检验科 854000 m
Author(s):
Zhang Yingying1;  Zhuo Yong2;  Ou Pei2;  Li Chenguang1;  Zhao Geng1; 2
1Department of Medical Laboratory, NHC Key Laboratory of Hormones and Development(Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin 300134, China; 2Department of Medical Laboratory, Changdu Tibetan Hospital of Tibet Autonomous Region, Changdu 854000, China Corresponding author: Zhao Geng, Email:zhaogeng5589@sohu.com
关键词:
中性粒细胞明胶酶相关脂质运载蛋白;  肾损伤因子-1;  糖尿病肾脏病;  2型糖尿病
Keywords:
Neutrophil gelatinase-related lipid carrier protein;  Kidney injury molecule-1;  Diabetic kidney disease;  Type 2 diabetes mellitus
DOI:
10.3760/cma.j.cn121383-20200502-05027
文献标志码:
A
摘要:
目的 检测藏区糖尿病肾脏病患者尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)及尿肾损伤分子-1(KIM-1)的水平,评估尿NGAL及KIM-1水平对藏区糖尿病肾脏病的临床诊断价值。方法 回顾性纳入2019年1—6月在昌都市藏医院住院的糖尿病肾脏病患者150例,根据24 h尿检连续尿白蛋白排泄率(UAER)水平分为:正常白蛋白尿(DM1)组、微量白蛋白尿(DM2)组、临床白蛋白尿(DM3)组,每组各50例,同时随机选取50名健康体检者作为对照组。比较各组的一般资料、相关生化指标及尿NGAL、尿KIM-1水平,采用Pearson相关分析检验尿NGAL、尿KIM-1与估算的肾小球滤过率(eGFR)、24 hUAER的相关性,采用受试者工作特征(ROC)曲线分析尿NGAL、尿KIM-1对藏区糖尿病肾脏病的临床诊断价值。结果 DM3组、DM2组、DM1组、对照组尿NGAL及尿KIM-1水平逐渐降低(P均<0.001); 尿NGAL及尿KIM-1与eGFR呈负相关(r=-0.798、-0.845,P均<0.05); 尿NGAL及尿KIM-1与24 hUAER呈正相关(r=0.792、0.821,P均<0.05); 尿NGAL单独用于诊断糖尿病肾脏病的曲线下面积(AUC)为0.876,尿KIM-1单独用于诊断糖尿病肾脏病的AUC为0.861,尿NGAL、尿KIM-1联合应用于糖尿病肾脏病的诊断AUC为0.914。结论 尿NGAL及KIM-1均可用于藏区糖尿病肾脏病的早期诊断和疾病进展预测,且两者联合检测的诊断价值更高。
Abstract:
Objective To detect the urine neutrophil gelatinase-related lipid carrier protein(NGAL)and kidney injury molecule-1(KIM-1)levels in diabetic kidney disease(DKD)patients with type 2 diabetes mellitus(T2DM)in Tibet and to evaluate their diagnostic value.Methods A total of 150 patients with DKD who were treated in Changdu Tibetan Hospital from January 2019 to June 2019 were enrolled. According to the 24 h urinary albumin excretion rate(UAER)level, these patients were divided into normal albuminuria(DM1)group, microalbuminuria(DM2)group, clinical albuminuria(DM3)group, with 50 cases in each group. And 50 healthy subjects were enrolled as control group. The general data, related biochemical indicators, urine NGAL and urine KIM-1 levels of each group were compared. Pearson correlation analysis was used to determine the correlation between urine NGAL, urine KIM-1 with estimated glomerular filtration rate(eGFR)and 24 h UAER. The receiver operating characteristic(ROC)curve analysis was used to compare the diagnostic value of urine NGAL and KIM-1 in patients with DKD.Results The urine NGAL and KIM-1 levels were higher in DM3 group, followed by DM2, DM1 and control group(all P<0.001). The urine NGAL and KIM-1 were negatively correlated with eGFR(r=-0.798,-0.845, all P<0.05). The urine NGAL and KIM-1 were correlated with 24 hUAER(r=0.792,0.821, all P<0.05). The area under ROC curve of urine NGAL alone in the diagnosis of patients with DKD was 0.876; the area under ROC curve of urine KIM-1 alone in the diagnosis of patients with DKD was 0.861. The diagnostic efficacy of NGAL combined with KIM-1 for detection of DKD patients with T2DM was higher than that of each test alone, and the area under ROC was 0.914.Conclusion Both urine NGAL and KIM-1 can be used for the early diagnosis and prediction of disease progression of patients with DKD in Tibet, and the combination detection of two indexes has higher diagnostic value.

参考文献/References:

[1] Collins AJ, Foley RN, Chavers B, et al. 2013 USRDS Annual Data Report:Atlas of chronic kidney disease and end-stage renal disease in the United States[J].Am J Kidney Dis,2014,63:e1-e478.
[2] 赵鹏鸣,王俭勤,梁耀军,等.内皮细胞损伤在糖尿病肾病发病机制中的作用[J].中国糖尿病杂志,2016,24(02):169-172.DOI:10.3969/j.issn.1006-6187.2016.02.020.
[3] 张萍.生化检测指标对糖尿病肾病早期诊断的临床价值[J].中国中药杂志社,2016:325-327.
[4] Gociman B, Rohrwasser A, Lantelme P, et al. Expression of angiotensinogen in proximal tubule as a function of glomerular filtration rate[J].Kidney Int,2004,65(6):2153-2160.DOI:10.1152/ajprenal.00405.2012.
[5] Togashi Y, Miyamoto Y. Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty(ZDF)rats[J].Exp Toxicol Pathol,2013,65(5):615-622.DOI:10.1016/j.etp.2012.06.005.
[6] AgnieszkaZ·yka A, Dumnicka P, Kus'nierz-Cabala B, et al. Markers of glomerular and tubular damage in the early stage of kidney disease in type 2 diabetic patients[J].Mediators Inflamm,2018,2018:7659243.DOI:10.1155/2018/7659243.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447-498.DOI:10.3760/cma.j.issn.1674-5809.2014.07.004.
[8] Levey AS,Inker LA,Coresh J.GFR estimation: from physiology to public health[J].Am J Kidney Dis,2014,63(5):820-834.DOI:10.1053/j.ajkd.2013.12.006.
[9] Foundation NK. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J].Am J Kidney Dis, 2007,49(2 Suppl 2):S12-S154.DOI:10.1053/j.ajkd.2006.12.005.
[10] National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD:2012 update[J].Am J Kidney Dis,2012,60(5):850-886.DOI:10.1053/j.ajkd.2012.07.005.
[11] Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria[J].Curr Opin Nephrol Hypertens,2011,20(3):246-257.DOI:10.1097/MNH.0b013e3283456546.
[12] 赵万霞,王何婷,任月秋,等.糖尿病肾病早期标志物研究新进展[J].国际内分泌代谢杂志,2018,38(3):192-195.DOI:10.3760/cma.j.issn.1673-4157.2018.03.012.
[13] Charlton JR, PortillaD, OkusaMD. A basic science view of acute kidney injury biomarkers[J].Nephrol Dial Transplant,2014, 29(7):1301-1311.DOI:10.1093/ndt/gft510.
[14] Han WK, Bailly V, Abichandani R,et al. Kidney injury molecule-1(KIM-1):a novel biomarker for human renal proximal tubule injury[J].Kidney Int,2002,62(1):237-244.DOI:10.1046/j.1523-1755.2002.00433.x.
[15] Nielsen SE, Reinhard H,Zdunek D,et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients[J].Diabetes Res Clin Pract,2012,97(1):71-76.DOI:10.1016/j.diabres.2012.02.007.
[16] Nowak N, Skupien J, Smiles AM, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development[J].Kidney Int,2018,93(5):1198-1206.DOI:10.1016/j.kint.2017.11.024.
[17] Gong J, Zhu R, Gong J, et al. Neutrophil gelatinase-associated lipocalin as a potential therapeutic integrator of glycolipid metabolic and inflammatory signaling[J].Int Surg J,2017,4(8):2381-2386.DOI:10.18203/2349-2902.isj20173376.
[18] Al-Refai AA, Tayel SI, Ragheb A, et al. Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria[J].Open J Nephrol,2014,4:37-46.DOI:10.4236/ojneph.2014.41006.
[19] Assal HS, Tawfeek S, Rasheed EA, et al. Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus[J].Clin Med Insights Endocrinol Diabetes,2013,6:7-13.DOI:10.4137/CMED.S12633.
[20] Bolignano D, Lacquaniti A, Coppolino G, et al.Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients[J].Kidney Blood Press Res,2009,32(2):91-98.DOI:10.1159/000209379.
[21] Yang YH, He XJ, Chen SR, et al. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy:one year observational follow-up study[J].Endocrine, 2009,36(1):45-51.DOI:10.1007/s12020-009-9187-x.
[22] Nielsen SE,Schjoedt KJ, Astrup AS, et al.Neutrophil gelatinase-associated lipocalin(NGAL)and kidney injury molecule 1(KIM1)in patients with diabetic nephropathy:a cross-sectional study and the effects of lisinopril[J].Diabet Med,2010,27(10):1144-1150.DOI:10.1111/j.1464-5491.2010.03083.x.
[23] 梁雅灵,杨茂君,李衍辉,等.尿L-FABP、KIM-1、NGAL和血清cystatin C在糖尿病肾病中的变化及意义[J].国际内分泌代谢杂志,2016,36(2):92-95,100.DOI:10.3760/cma.j.issn.1673-4157.2016.02.005.
[24] 李晨晨,张蓓茹,何平,等.尿KIM-1和NGAL在评估慢性肾脏病肾小管间质损伤中的作用[J].国际检验医学杂志,2019,40(5):540-545.DOI:10.3969/j.issn.1673-4130.2019.05.008.

相似文献/References:

[1]赵耕 牛文彦.中性粒细胞明胶酶相关脂质运载蛋白在代谢相关肾损伤中的应用价值分析[J].国际内分泌代谢杂志,2022,42(04):272.[doi:10.3760/cma.j.cn121383-20210928-09084]
　Zhao Geng,Niu Wenyan..Application value of neutrophil gelatinase related lipid carrier protein in metabolism related renal injury[J].International Journal of Endocrinology and Metabolism,2022,42(05):272.[doi:10.3760/cma.j.cn121383-20210928-09084]

备注/Memo

备注/Memo:
基金项目:西藏自治区自然科学基金项目(XZ2019ZRG-143) 通信作者:赵耕,Email:13212156976@163.co
更新日期/Last Update: 2020-09-20